I
Isomorphic Labs
AI-first drug design and discovery company
About Isomorphic Labs
Isomorphic Labs is a UK-based AI drug discovery and development company that uses artificial intelligence to design new medicines. It was founded in 2021 within Alphabet as a spin-out of DeepMind by Sir Demis Hassabis, who serves as its chief executive officer and also leads Google DeepMind, and it is headquartered in London's King's Cross.
The company builds on the scientific approach behind AlphaFold, the DeepMind system for predicting protein structures. Together with Google DeepMind, Isomorphic Labs co-developed AlphaFold 3, a model that predicts the structure and interactions of proteins, DNA, RNA, small molecules and other biomolecules. It is developing a unified AI drug design engine that combines predictive and generative models to identify drug targets, design candidate molecules and predict their properties, aiming to make drug discovery faster and more likely to succeed.
Isomorphic Labs applies this engine both to its own internal pipeline and to collaborations with pharmaceutical companies. It is advancing drug design programmes across multiple therapeutic areas and drug modalities, with a focus on moving its own candidates towards clinical development, and it has entered research partnerships with large pharmaceutical companies under which it can receive upfront payments, milestones and royalties.
The company brings together researchers from machine learning, structural biology, chemistry, physics and medicine, and positions itself as an AI-first drug design company with the long-term mission of solving disease with the help of artificial intelligence.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 408
- Open positions
- 17
- Dealroom signal
- 96.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Drug Development, Core AI, Verified Unicorns and $1B Exits, Tech for Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- B2B
Knowledge graph
Market map
Deep Tech flywheel in Europe
Market map
UK Techbio landscape
Market map
Computational Biology & Chemistry startups in Europe
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in United Kingdom
Analysis
Isomorphic Labs’ $5B Series C is the largest venture round in European history
Nov 19, 2026
Analysis
The Bay Area added 11 decacorns in 2026, Europe 9 (New Palo Alto 4)
Nov 17, 2026
Analysis
European health companies to watch in 2026
Oct 7, 2026
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B | May 2026 | $2.1B | $8.4B | GV · MGX · CapitalG · Alphabet | Google | ↗ |
| LATE VC | Mar 2025 | $600M | $2.4B | GV · Thrive Capital | ↗ |
Growth signals
Latest recorded traffic for Isomorphic Labs is 130K monthly website visits, up 38.3% over the last three months. Isomorphic Labs's team grew 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Isomorphic Labs in the London ecosystem
The Isomorphic Labs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
MGX
CapitalG
Alphabet | Google
UK Sovereign AI
Temasek
Series B and later3 investors entered at this stage
Google DeepMind
Thrive Capital
GV
Source: Dealroom Talent Intelligence.
See Isomorphic Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.
Isomorphic Labs raises $5B, six months after its $2.1B round, to push AI-designed drugs toward trials
DeepMind spinout Isomorphic Labs in talks to raise about $5B at a $50B valuation
Radical Ventures' Aaron Rosenberg on DeepMind's alumni wave






